Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan + Temozolomide + Bevacizumab in Relapsed/Refractory Soft Tissue Sarcoma
NCT07457775Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2026
- Primary completion
- Jan 2028
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan in soft tissue sarcoma (STS), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Progression-Free Survival at 24 months and Adverse Events at 24 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07457775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07457775.